QuidelOrtho to invest 750K in heart disease awareness

By LabPulse.com staff writers

June 22, 2022 -- QuidelOrtho on Monday announced that its subsidiary, Quidel, will invest funding totaling $750,000 and support over the next three years in American Heart Association (AHA) initiatives to promote cardiovascular and brain health, prevent heart disease and stroke, and support research.

As part of the collaboration, Quidel will invest the funding and give support for campaigns and initiatives led by the AHA's San Diego division.

"As we remain dedicated to addressing unmet needs in diseases, our top priority continues to be to elevate attention to heart disease," Douglas Bryant, chairman and CEO of QuidelOrtho, said in a statement.

Cardio Diagnostics to become public company
Cardio Diagnostics has entered into a business agreement to become a publicly listed company through a deal with special-purpose acquisition company (SPAC)...
Quidel completes Ortho deal, emerges as QuidelOrtho
Quidel announced on May 27 that it has completed its acquisition of Ortho Clinical Diagnostics. The combined diagnostic testing company will be known...
BrainBox secures $3.5M NINDS grant
Diagnostics developer BrainBox Solutions has been awarded a $3.5 million Small Business Innovation Research grant from the U.S. National Institute of...
Study to use genetic testing to evaluate heart disease
Dignity Health in Arizona is starting a research study that will use genetic testing to identify individuals at risk of developing heart disease.
Revenues from coagulation lab and POC tests near $4B in 2021
The 2021 global market for lab-based and point-of-care (POC) coagulation tests neared $4 billion in 2020, with prothrombin time and d-dimer tests...

Copyright © 2022 LabPulse.com

Last Updated mp 6/22/2022 7:04:24 AM